RAJAF — Cordyceps Sunshine Biotech Holdings Co Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMid Cap
- $951.19m
- $951.60m
- $0.88m
Annual income statement for Cordyceps Sunshine Biotech Holdings Co, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | R2021 December 31st | R2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS/A | 20-F | 20-F | 20-F |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 0.135 | 0 | 0.053 | 0.883 |
| Cost of Revenue | ||||
| Gross Profit | 0.094 | — | 0.04 | 0.766 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Depreciation and Amortization | ||||
| Total Operating Expenses | 0.126 | 0.119 | 0.468 | 0.657 |
| Operating Profit | 0.009 | -0.119 | -0.415 | 0.225 |
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -0.012 | -0.119 | -0.415 | 0.199 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -0.013 | -0.119 | -0.415 | 0.242 |
| Net Income Before Extraordinary Items | ||||
| Extraordinary Items | ||||
| Net Income | -0.013 | -0.491 | -0.72 | 0.824 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -0.013 | -0.491 | -0.72 | 0.824 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0 | -0.001 | -0.004 | 0.002 |